Results
The model showed that FeNO, was associated with lower total cost than SC
(US $1333 vs US $1452 average cost per patient), and higher QALYs
(0.93 vs. 0.92 average per patient); showing dominance. The probability
that MS provides a more cost-effective use of resources compared with
standard therapy exceeds 99% for all willingness to pay thresholds